VCYT - Veracyte, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Veracyte, Inc.

6000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650 243 6300

Full-time employees787

Key executives

NameTitlePayExercisedYear born
Mr. Marc A. StapleyCEO & Director1.25MN/A1970
Ms. Bonnie H. AndersonCo-Founder & DirectorN/AN/A1958
Ms. Rebecca ChambersExec. VP & CFO772.41kN/A1978
Ms. Annie McGuireExec. VP, Gen. Counsel & Chief People Officer633.65kN/A1981
Mr. Jonathan WygantVP & Chief Accounting OfficerN/AN/A1971
Mr. Steven FrenchSr. VP & Chief Information OfficerN/AN/AN/A
Ms. Tracy MorrisVP of Global Corp. CommunicationsN/AN/AN/A
Mr. Robert BraininExec. VP & Chief Bus. OfficerN/AN/A1971
Dr. Fabienne Hermitte Ph.D.Sr. VP of Global Quality & Regulatory AffairsN/AN/AN/A
Dr. John Leite Ph.D.Sr. VP and GM of Pulmonology & Market AccessN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Corporate governance

Veracyte, Inc.’s ISS governance QualityScore as of 1 June 2023 is 5. The pillar scores are Audit: 5; Board: 2; Shareholder rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.